Massimiliano Salati

Dr. Massimiliano Salati


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
FCFrancesca Corti
Francesca Corti
SLSara Lonardi
Sara Lonardi
RIRossana Intini
Rossana Intini
MSMassimiliano Salati
Massimiliano Salati
EFElisabetta Fenocchio
Elisabetta Fenocchio
FPFilippo Pietrantonio
Filippo Pietrantonio

6 August 2018 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAndrea Botticelli
Andrea Botticelli
BCBruna Cerbelli
Bruna Cerbelli
LLLuana Lionetto
Luana Lionetto
IZIlaria Grazia Zizzari
Ilaria Grazia Zizzari
MSMassimiliano Salati
Massimiliano Salati
PMPaolo Marchetti
Paolo Marchetti
Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% of patients experience a durable benefit, while the vast majority demonstrate primary or acquired resistance. Recently, indoleamine 2,3-dioxygenase (IDO) activity has been proposed as a possible mechanism of resistance to anti-PD-1 treatment leading to an immunosuppressive microenvironment. Pre-treatment serum concentrations of tryptophan (trp) and kynurenine (kyn) were measured by high-performance liquid chromatography tandem mass spectrometry in NSCLC patients treated with second-line nivolumab. The IDO activity was expressed with kyn/trp ratio. The associations between kyn/trp ratio and early progression, performance status (PS), age, sex, brain metastases, pleural effusion, progression free survival (PFS) and overall survival (OS) were analyzed using Spearman test and Mann–Whitney test. Twenty-six NSCLC patients were included in our study; 14 of them (54%) presented early progression (< 3 months) to nivolumab treatment. The median value of kyn/trp ratio was 0.06 µg/ml and the median value of quinolinic acid was 68.45 ng/ml. A significant correlation between early progression and higher kyn/trp ratio and quinolinic acid concentration was observed (p = 0.017 and p = 0.005, respectively). Patients presenting lower values of kyn/trp ratio and quinolinic acid levels showed longer PFS (median PFS not reached versus 3 months; HR: 0.3; p = 0.018) and OS (median OS not reached vs 3 months; HR: 0.18; p = 0.0005). IDO activity, expressed as kyn/trp ratio, is associated with response to immunotherapy; in particular, higher kyn/trp ratio could predict resistance to anti-PD-1 treatment. These preliminary results suggest the possibility of using anti-PD-1 plus IDO inhibitor in those patients with high level of kyn/trp ratio.

1 September 2019 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MSMassimiliano Salati
Massimiliano Salati
GOGiulia Orsi
Giulia Orsi
ESElisabeth Smyth
Elisabeth Smyth
GBGiordano Beretta
Giordano Beretta
FVFernando De Vita
Fernando De Vita
SCStefano Cascinu
Stefano Cascinu

27 March 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAndrea Botticelli
Andrea Botticelli
MSMassimiliano Salati
Massimiliano Salati
FPFrancesca Romana Di Pietro
Francesca Romana Di Pietro
LSLidia Strigari
Lidia Strigari
BCBruna Cerbelli
Bruna Cerbelli
PMPaolo Marchetti
Paolo Marchetti
The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection. Patients with stage IIIB–IV NSCLC receiving nivolumab at Sant’Andrea Hospital and Regina Elena National Cancer Institute from June 2016 to July 2017 were enrolled onto this study. Major clinicopathological parameters were retrieved and correlated with patients’ survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision making process. A total of 102 patients were included in this study. The median age was 69 years (range 44–85 years), 69 (68%) were male and 52% had ECOG PS 0. Loco-regional/distant lymph nodes were the most commonly involved site of metastasis (71%), followed by lung parenchyma (67%) and bone (26%). Overall survival (OS) in the whole patients’ population was 83.6%, 63.2% and 46.9% at 3, 6 and 12 months, respectively; while progression-free survival (PFS) was 66.5%, 44.4% and 26.4% at 3, 6 and 12 months, respectively. At univariate analysis, age ≥ 69 years (P = 0.057), ECOG PS (P < 0.001), the presence of liver (P < 0.001), lung (P = 0.017) metastases, lymph nodes only involvement (P = 0.0145) were significantly associated with OS and ECOG PS (P < 0.001) and liver metastases (P < 0.001), retained statistical significance at multivariate analysis. A prognostic nomogram based on three variables (liver and lung metastases and ECOG PS) was built to assign survival probability at 3, 6, and 12 months after nivolumab treatment commencement. We developed a nomogram based on easily available and inexpensive clinical factors showing a good performance in predicting individual OS probability among NSCLC patients treated with nivolumab. This prognostic device could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enrollment onto clinical trials.

12 October 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MSMassimiliano Salati
Massimiliano Salati
MPM. Pifferi
M. Pifferi
CBC. Baldessari
C. Baldessari
FBF. Bertolini
F. Bertolini
CTC. Tomasello
C. Tomasello
FBF. Barbieri
F. Barbieri
Stevens–Johnson syndrome (SJS) is a type IV hypersensitivity reaction, mainly to drugs, that presents as mucocutaneous blistering and sloughing and which may follow a devastating clinical course. Although its incidence is roughly 1–2 cases per million/year, the mortality rate may be as high as 30% when the condition progresses to toxic epidermal necrolysis (TEN; also known as Lyell’s syndrome). Many different drug classes have been implicated as causes of SJS (e.g. antibiotics, NSAIDs, anticonvulsants) [1]. Among them, immune checkpoint inhibitors, such as the anti-PD1 agent nivolumab, are emerging culprits. This is especially relevant considering that the use of such drugs in oncology is becoming more widespread in an ever-increasing number of cancer types. It has recently been reported that up to 22%...

1 August 2015 in Annals of Epidemiology
Verified
Journal Article
Closed access
MMMufid El Mistiri
Mufid El Mistiri
MSMassimiliano Salati
Massimiliano Salati
LMLuigi Marcheselli
Luigi Marcheselli
AAAdel Attia
Adel Attia
SHSalah Habil
Salah Habil
MFMassimo Federico
Massimo Federico